Harmony Biosciences Hldg Inc (HRMY) financials
Harmony Biosciences Hldg revenue and earnings by year
Harmony Biosciences Hldg's revenue was $868 million in the fiscal year to December 31, 2025, up 21.5% from the year before. Net income was $159 million, 18.3% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 129.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 868 | 715 | 582 | 438 | 305 | 160 | 6 |
| Revenue growth | 21.5% | 22.8% | 32.9% | 43.4% | 91.2% | 2564.6% | — |
| Gross profit | 670 | 558 | 461 | 354 | 250 | 132 | 4 |
| Gross margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% |
| Operating income | 208 | 191 | 192 | 120 | 88 | 17 | -146 |
| Operating margin | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% | 10.6% | -2433.8% |
| Net income | 159 | 145 | 129 | 181 | 35 | -37 | -152 |
| Net margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2535.1% |
| Diluted EPS | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | -$2.48 | — |
| Free cash flow | 348 | 219 | 219 | 144 | 98 | -3 | -76 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open HRMY in Markets.
See also: HRMY valuation and P/E history · HRMY returns
No forecast, no recommendation. This page describes Harmony Biosciences Hldg Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.